Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program

PR Newswire June 8, 2020

CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

PR Newswire June 2, 2020

CASI Pharmaceuticals Announces First Quarter 2020 Financial Results

PR Newswire May 11, 2020

CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference

PR Newswire April 7, 2020

CASI Pharmaceuticals Announces Full Year 2019 Financial Results

PR Newswire March 16, 2020

CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

PR Newswire December 3, 2019

CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

PR Newswire November 12, 2019

CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly

PR Newswire November 7, 2019

CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President

PR Newswire September 19, 2019

China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product

PR Newswire September 16, 2019

CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City

PR Newswire September 5, 2019

CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference

PR Newswire September 3, 2019

CASI Pharmaceuticals Announces Launch of EVOMELA® (melphalan for injection) in China

PR Newswire August 12, 2019

CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results

PR Newswire August 9, 2019

CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy

PR Newswire June 17, 2019

CASI Pharmaceuticals To Present At The 2019 BIO International Convention

PR Newswire June 3, 2019

CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results

PR Newswire May 15, 2019

INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

PR Newswire April 18, 2019

CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics

PR Newswire April 17, 2019

CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer

PR Newswire April 2, 2019